Mar 20, 2025 9:20am EDT MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Mar 19, 2025 11:00am EDT MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
Feb 27, 2025 8:51am EST MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Feb 26, 2025 8:47am EST MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
Feb 24, 2025 4:30pm EST MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
Feb 04, 2025 8:51am EST MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
Jan 07, 2025 9:12am EST MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
Dec 19, 2024 8:47am EST MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
